Pre-commercial procurement to assign research and development services in the context of the project called NYMPHA — MD, related to the ‘Search for Mobile Technological Solutions to Support Health Workers and Patients with the Care And Management of Bipolar Disorder’.
Provincia Autonoma di Trento — Agenzia Provinciale per gli Appalti e contratti — Servizio appalti — Ufficio gare | Published September 2, 2015 - Deadline October 30, 2015
The NYMPHA-MD pre-commercial procurement project has as its object industrial research and experimental development designed to look for mobile technological solutions to support health workers and patients in the care and management of bipolar disorder.
According to the Procurement Agreement of 6.1.2015, the Provincia Autonoma di Trento (PAT) (Italy) shall act as the contracting authority, in its own name and on behalf of the following contractors: Region Hovedstaden Psychiatric Center Copenhagen (Region H) and the Corporacio Sanitaria Parc Tauli de Sabadell in Barcelona (CSPT).
The NYMPHA-MD project is co-funded by the European Commission in the context of the Seventh Framework Programme for research and innovation (FP7/2007-2013), according to the ‘CP-CSA for PCP’ funding scheme.
This procedure shall be divided into three phases:
— Phase 1 (Solution Design) has the object of planning innovative technological solutions and producing the related feasibility study. Phase 1 provides for a maximum of 4 (four) successful bidders, with each of which the Administration will proceed to stipulate a Framework Agreement, the draft of which is enclosed with this tender notice, which will regulate the methods and conditions that are the object of each phase. The successful bidders shall be required to carry out the activities detailed in article 6 of the Framework Agreement. By the contractual deadline for phase 1, successful bidders must deliver all the documents provided for by article 6 of the Framework Agreement. The contracting authority will see to verifying the results, in accordance with the provisions of article 10 of the Framework Agreement and by the term established therein.
— Successful bidders in phase 1 who have passed the checks on the results of their phase 1 activities will be invited to participate in phase 2. ‘Phase two’ (Prototype Development) has the scope of developing and integrating the prototype for the innovative solution proposed. The phase 2 bid will involve presenting a development programme for the prototype, including the design and technical specifications for this, and a financial-business plan. The tender procedure shall be regulated by the relative letter of invitation. Phase 2 provides for a maximum of 3 (three) successful bidders, with whom the relative documents for the phase will be signed. By the contractual deadline for phase 2, successful bidders must deliver the prototype for the innovative solution proposed, accompanied by technical information sheets and the results of the preliminary tests carried out, as in article 6 of the Framework Agreement. The contracting authority will see to verifying the results, in accordance with the provisions of article 10 of the Framework Agreement and by the term established therein.
— Successful bidders in phase 2 who have passed the checks on the results of their phase 2 activities will be invited to participate in phase 3. ‘Phase three’ (original development of a limited volume of first products or services in the form of a test series) has the scope of carrying out initial development of a limited quantity of prototype products/services in the form of a test series. The phase 3 bid will involve presenting a programme of experimentation in a real environment for a limited number of prototypes. Phase 3 provides for 2 (two) successful bidders, with whom the relative implementation documents for the phase will be signed and who will be required to try out their innovative solution with the three health service providers involved (Trento, Copenhagen and Barcelona) on a selected sample of patients, according to the provisions of article 6 of the Framework Agreement. Once the experimentation has terminated, the two successful bidders must hand in a final report on the results of the pre-commercial procurement. This report will be checked by a special committee, together with the successful bidders, in accordance with the provisions of article 10 of the Framework Agreement and by the term established therein.
As the PCP assumes — in every phase — competition between at least two economic operators, PAT will not continue with the procedure if this condition is not met.